📢 We’re thrilled to welcome Neil Verma as our new Senior Director & Head of Portfolio and Program Management! With over 18 years of #Biotech experience, Neil brings expertise in scaling operations, advancing complex manufacturing programs, and driving operational excellence. His leadership will play a key role in supporting our mission to advance #CellTherapy manufacturing. Please join us in welcoming Neil to the BioCentriq team! #BioCentriq #Leadership #Biotech #CellTherapy #CDMO #CGT #PMO
BioCentriq
Pharmaceutical Manufacturing
Newark, New Jersey 4,490 followers
Accelerating cell therapy innovation with CDMO solutions from development to commercialization.
About us
BioCentriq is a premier contract development and manufacturing organization (CDMO) dedicated to advancing cell therapy. Since 2019, the company has specialized in GMP autologous and allogeneic cell therapies, offering end-to-end clinical-to-commercial capable services tailored to clients’ unique needs. Operating from two state-of-the-art U.S.-based facilities, BioCentriq provides a comprehensive range of services, including technology transfer and new technology evaluations, process and analytical development, cGMP manufacturing, quality control lot release, and stability studies. The company’s expertise spans diverse cell therapy modalities, such as T-cell (CAR-T, TCR), NK-cell, iPSC, and MSC-based products. With its proprietary LEAP™ manufacturing platform, BioCentriq accelerates service timelines while offering standardized and customizable solutions, including traditional fee-for-service, hybrid and person-in-plant operations, dedicated cleanroom capacity, and flexible service and contract arrangements. In addition to its technical capabilities, BioCentriq operates the Cell and Gene Therapy Experiential Learning Center, a training facility which provides hands-on and virtual instruction under the guidance of industry-experienced instructors and subject matter experts. The program has trained hundreds of participants, hosted major pharmaceutical companies, and integrates next-generation technologies and concepts into its curriculum including: Industry 4.0 and Lean principles, predictive analytics, augmented reality, and electronic batch record systems. Backed by GC Corporation, a South Korea-based leader in the healthcare, pharmaceutical and biotechnology industry, BioCentriq combines global expertise with a flexible working relationship, set to empower clients to develop and deliver cutting-edge, personalized therapies with unmatched precision and efficiency.
- Website
-
https://biocentriq.com
External link for BioCentriq
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Newark, New Jersey
- Type
- Privately Held
- Founded
- 2019
- Specialties
- CDMO, Process Development, Analytical Development, GMP Manufacture, QC Lot Release, Workforce Training & Development, Allogeneic Cell Therapy, and Autologous Cell Therapy
Locations
-
Primary
138 Summit St
Newark, New Jersey 07103, US
-
9 Deerpark Dr
Monmouth Junction, New Jersey 08852, US
-
211 Warren Street
Newark, NJ 07103, US
Employees at BioCentriq
Updates
-
🚨 BioCentriq Expands with New Princeton, NJ HQ and Advanced Cell Therapy Manufacturing Facility! We're proud to announce a transformative milestone in BioCentriq's journey - our expansion to Princeton, New Jersey with a new 60,000 sq. ft. state-of-the-art #CellTherapy manufacturing facility that will serve as our new company headquarters! Key highlights of our expansion: 🔹Compliments our Newark, NJ site to create a regional manufacturing network. 🔹$12M capital investment in cutting-edge equipment & digital systems. 🔹6 independent ISO 7 cleanrooms with advanced technology. 🔹Integrated development & quality control labs. 🔹30,000 sq. ft. expansion space for additional capacity. This strategic expansion strengthens our ability to support #CellTherapy innovators from #Clinical to #Commercial scale, building on our expertise in #CAR-T, #NK Cells, #MSC, #iPSC-based products and more. "Securing this facility marks a significant milestone in our growth and reinforces our mission to deliver high-quality, scalable manufacturing solutions for cell therapy innovators globally" said Syed T. Husain Chairman and CEO of BioCentriq. We’re ready to deliver on our promise of scalable, high-quality solutions for the cell therapy industry! 👉 To Learn More: https://bit.ly/3ZDV87E 👉 For Project Needs: https://bit.ly/49DX9VO #BioCentriq #CellTherapy #LifeSciences #Expansion #Innovation #CDMO
-
BioCentriq's Industry Training & Workforce Development Program is transforming how we prepare the next generation of cell therapy professionals. Our state-of-the-art "Experiential Learning Center" delivers unparalleled hands-on training through: - Real-world experience in active GMP environments - Direct mentorship from industry-leading experts - Immersive learning with cutting-edge technologies including automation, predictive analytics, and augmented reality Our track record speaks for itself: hundreds of successful graduates and strategic partnerships with leading organizations in the field. We're not just training individuals - we're building the workforce that will drive the future! Transform your team's capabilities and elevate your expertise. Contact us! info@biocentriq.com
-
We are pleased to announce Syed T. Husain has been appointed Chairman of the Board at BioCentriq, in addition to his role as CEO. Since joining the company, Syed has driven impactful changes that have positioned BioCentriq for long-term success. In his expanded role as Chairman, Syed will continue to guide BioCentriq’s transformation and growth, further solidifying our position as a leader in cell therapy development and manufacturing within the CDMO industry. Please join us in congratulating Syed on this well-deserved appointment and his continued dedication to BioCentriq’s success. #Leadership #BioCentriq #CEO #Chairman #BoardofDirectors #CellTherapy #CDMO
-
Please join us in welcoming Chithkala (Ck) Harinarayan as BioCentriq's new VP & Head of Quality and Compliance! Ck brings 25+ years of expertise in Cell Therapy and Biologics, with deep experience across Quality, Development, and Technical Operations. At Kite Pharma, she was Head of Clinical GMP Quality, driving CMC strategy for the pipeline and successful commercialization of Tecartus and Yescarta. Her track record includes over 25 successful regulatory inspections and overseeing the design and operationalization of GMP facilities at both Genentech and Kite Pharma. Welcome to the team, Ck! 🎉 #Leadership #Biotech #CGT #BioCentriq #CDMO #QualityCompliance #AdvancedTherapies #GMP
-
Please join us in welcoming Sun Ra Bullins as BioCentriq’s new VP and Head of Technical Operations! Sun Ra brings extensive expertise in #biopharmaceutical operations, with a strong focus on #GMP production, process development, and cleanroom design. Throughout his career, he has built and led high-performing teams, turned around complex manufacturing operations, and driven innovation in #CellAndGeneTherapy. His leadership will enhance operational efficiency, foster collaboration, and strengthen our commitment to delivering exceptional solutions for #AdvancedTherapy manufacturing. Welcome to the team, Sun Ra! 🎉 #Leadership #CellTherapy #BioCentriq #CGT #CDMO #advancedtherapies #Operations
-
🔴 We’re live at Advanced Therapies USA 2024! If you're in Philadelphia, now’s the perfect time to connect with Chathuranga De Silva Ph.D. and Mary Loveras. They’re here to discuss the latest in #CellAndGeneTherapy and how BioCentriq can guide your projects down the path to #ClinicalSuccess. Whether you’re seeking expert guidance or a strategic partnership to overcome your project challenges, we’ve got you covered. Simply reach out to Chat or Mary and schedule your one-on-one meeting today! Let’s make it happen at Advanced Therapies! #AdvancedTherapiesUSA #Biotech #LifeSciences #CGT #CDMO #BioCentriq #CellTherapy
-
In a recent article by Inside Precision Medicine, editor Jonathan D. Grinstein, PhD brings together insights from industry experts in "The End of the Beginning for Cell and Gene Therapy – Part 2." The article covers the current state of #CellAndGeneTherapy, balancing scientific promise with regulatory and manufacturing hurdles. David Smith, VP of Development at BioCentriq, discusses how #CDMOs are essential in advancing early-stage #ClinicalTrials and scaling processes as therapies evolve. 🔗 Read the full article here: https://lnkd.in/efNQijZZ #CellAndGeneTherapy #BiotechInnovation #CDMO #CellTherapy #Biopharma #ClinicalDevelopment #RegulatoryChallenges #TherapyDevelopment #BioCentriq
-
📢 BioCentriq Welcomes New Commercial Leadership! We’re thrilled to announce the appointment of Joe Sinclair as our new VP and Head of Commercial! With over 15 years' experience in the life sciences sector, Joe is recognized for his strategic insight in driving commercial growth, operational excellence, and fostering strong client partnerships across #CDMO organizations. His expertise in building high-performing teams and delivering client-centered solutions is invaluable as we embark on our next phase of growth. Please join us in welcoming Joe to the BioCentriq family! #BioCentriq #Leadership #LifeSciences #CDMO #CellTherapy #CGT #WelcomeToTheTeam
-
🎉 Cheers to Travis Wright! We're excited to announce that after a successful internship, he's joining BioCentriq full-time with our #Manufacturing team! Travis brought energy, dedication, and invaluable contributions to his role, and we can’t wait to see him continue to thrive. Special thanks to the Alliance for Regenerative Medicine and the GROW RegenMed Internship Program for making this journey possible. "My time at BioCentriq was nothing short of outstanding! As a Commercial Intern, I gained valuable insights into Business Development and Marketing. I was also fortunate to shadow the Manufacturing Science and Technology (MSAT) team during tech transfer for one of BioCentriq's GMP clients. Being exposed to a cross functional team has provided me the opportunity to understand how a CDMO operates. Above all, I am grateful for the people I have met and the experiences that I have made." - Travis Wright